Science Minister Lord Vallance used a London Tech Week speech on 9 June 2026 to set out a clear government line: research strength is not enough on its own, and policy now has to move discoveries through finance, regulation, procurement and adoption so that companies start in the UK, scale in the UK and remain in the UK. According to the published GOV.UK transcript, he placed science and technology alongside the government's growth mission and the Modern Industrial Strategy rather than treating them as an annex to industrial policy. (gov.uk) For Policy Wire readers, the significance is less in the speech's historical framing than in the operating model it described. The central proposition is that Whitehall will try to use several levers at once: long-term R&D settlements, sector plans, state-backed finance, regulatory reform and public procurement. That is a broader state role than a simple grants programme, and it gives departments a wider set of delivery tests over the next spending period. (gov.uk)
Vallance said the spending review commits £86 billion to public R&D, with UKRI being reshaped around the full pipeline from discovery to commercialisation. In the speech, he set out a structure of £14.5 billion for curiosity-driven research, £8 billion for applied work linked to government and societal priorities, £7 billion for innovative companies, plus £8 billion for skills, infrastructure and facilities; DSIT's 2026-27 Estimate separately confirms £86 billion of public R&D over the period and £38.6 billion for UKRI across four years. (gov.uk) That matters for universities, research institutes and innovation-led firms because it indicates ministers are trying to defend the basic-research settlement while attaching more visible routes into policy priorities and company growth. The same package also points to a larger role for ARIA, with the speech referring to a further £1 billion and Spending Review papers stating at least £1 billion over the period to scale the agency. (gov.uk)
The speech linked this funding architecture to the Digital and Technologies Sector Plan within the 10-year Modern Industrial Strategy. Government documents identify six frontier technologies as priority areas: advanced connectivity technologies, artificial intelligence, cyber security, engineering biology, quantum technologies and semiconductors. Vallance said £4 billion has been invested across these areas since publication of the plan, alongside the launch of a Sovereign AI venture fund; separate government material shows Sovereign AI was launched in April 2026 and presented as a £500 million fund for UK AI firms. (gov.uk) In policy terms, this is an attempt to stop frontier technology from being treated as a narrow science brief. The sector plan language stresses resilience, productivity and national security as well as growth, which means businesses should expect these technologies to be judged not only by headline valuations but by their use in public services, critical infrastructure and strategic supply chains. (gov.uk)
Quantum was the clearest example. Vallance said the government is moving from R&D support to market creation, pointing to a procurement commitment for scaled quantum computers, a new Quantum Growth Alliance and a further £12 million funding pool for hybrid quantum-classical algorithms flagged for later in the week. The GOV.UK transcript lists initial alliance members from finance, life sciences, energy, defence and telecoms, including HSBC, Barclays, Standard Chartered, GSK, BP, Rolls Royce, BAE Systems, BT, Vodafone and QinetiQ. (gov.uk) This sits on top of the government's March 2026 quantum package, which set out support worth up to £2 billion and an ambition to become the first country to deploy quantum computers at scale by the early 2030s. For corporate strategy teams, the practical point is that ministers are trying to create a domestic demand signal before fully scaled systems arrive, using procurement and early adopters to reduce commercial uncertainty for UK suppliers. (gov.uk)
Engineering biology was presented as the next test of that approach. Vallance announced a £45 million Engineering Biology Value and Sharing Growth Fund to support capabilities such as DNA writing, research automation, biomanufacturing and the use of biological data with AI models. He said this would sit alongside £196 million for research and innovation and £184 million for scale-up infrastructure; government material published in April also describes engineering biology as one of the six frontier technologies and highlights the same £196 million and £184 million commitments. (gov.uk) For firms working in bioprocessing, tools, platform biology and industrial biotech, the message is that Whitehall is now focusing on the difficult middle of the pipeline: shared facilities, manufacturing capacity and regulatory routes to market. That is the part of the system where promising UK science has often struggled to convert into domestic production and long-term company growth. (gov.uk)
Vallance was explicit that the next policy problem is no longer start-up formation alone but scale. He said the British Business Bank now has £25.6 billion of permanent capacity and aims to mobilise at least 10 new funds by 2030. Government papers support the first point: the bank's capacity was expanded to £25.6 billion, with a £4 billion Industrial Strategy Growth Capital Initiative intended to focus investment on priority sectors. (gov.uk) The speech also tied scale-up finance to pension reform. That is consistent with the wider policy direction: the Pension Schemes Act received Royal Assent on 29 April 2026, and the Department for Work and Pensions says it is intended to create larger funds with broader investment capacity, including in UK businesses and infrastructure. For founders, boards and institutional investors, the issue now is whether these reforms produce repeat growth capital at series-B and later stages, rather than one-off announcements. (gov.uk)
Another important part of the speech was the attempt to use regulation as an adoption tool rather than only as a gatekeeper. Vallance said the Regulatory Innovation Office is using the spending review to back faster, safer deployment of new technology, starting with what he described as a first-of-its-kind sandbox to test AI models that predict drug safety risks. An MHRA statement published the same day says the sandbox will let companies and researchers test AI tools for medicines safety, with the first phase due to begin from summer 2026. (gov.uk) He paired that with a strong procurement message. The speech put annual government procurement at £400 billion, and Cabinet Office material published in April says the public sector spends more than £400 billion a year buying goods and services. If departments can translate even a modest share of that spend into early demand for innovative suppliers, procurement could become a more direct industrial policy instrument than many grant schemes. (gov.uk)
The final read-across is institutional. Vallance argued that the UK innovation system is stronger than it was a decade ago on spin-outs and entrepreneurship, but still loses value when firms fail to scale domestically. He linked that gap to four delivery levers: finance, regulation, procurement and skills, while also pointing to the Global Talent Fund as part of the growth offer. (gov.uk) For policy professionals, the speech is best read as a delivery brief rather than a conference set-piece. The government has now stated, in public and across multiple documents, that it wants a joined-up route from research to adoption in quantum, engineering biology, AI and other frontier technologies, with stated public benefits ranging from medicines development to more resilient infrastructure. The test over the next 12 to 24 months will be whether departments can turn that model into repeatable procurement, faster regulatory decisions, investable scale-up finance and clearer regional delivery through the Modern Industrial Strategy. (gov.uk)